

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007130 A1

(51) International Patent Classification⁷: **A61K 9/00**, 31/00, 47/22

(21) International Application Number: PCT/EP2004/007591

(22) International Filing Date: 9 July 2004 (09.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 10/618,548 11 July 2003 (11.07.2003) US

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PATEL, Ashish, Anilbhai [IN/US]; 20 New Road #6A, Kendall Park, NJ 08824 (US). DAVILA, Pablo [US/US]; 130 Woods Road, East Windsor, NJ 08520 (US).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/007130 A1

(54) Title: STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING AN ACE INHIBITOR

(57) Abstract: A pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutically acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the weight percents are based on the total weight of the pharmaceutical composition. Preferably, the pharmaceutical composition is stable, and the formation of an internal cyclization product, and/or ester hydrolysis product, and/or oxidation product within the composition, has been reduced or eliminated. The ACE inhibitor is selected from the group consisting of quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazepril, lisbenzapril, dclapril, cilazapril and combinations thereof. Advantageously, the stabilized pharmaceutical compositions of the invention preserve the ACE inhibitor or a pharmaceutically acceptable salt thereof present in the compositions from degradation.

Stable Pharmaceutical Compositions Containing an ACE InhibitorField of the Invention

The invention relates to pharmaceutical compositions comprising an angiotensin converting enzyme (ACE) inhibitor, an alkali or alkaline earth metal carbonate, and hydroxypropyl cellulose. More particularly, the invention relates to stable pharmaceutical compositions wherein the formation of an internal cyclization product and/or ester hydrolysis product and/or oxidation product, has been reduced or eliminated.

Background of the Invention

There are a number of pharmaceutical compositions which suffer from instability problems due to the fact that the active component is susceptible to certain types of degradation, thereby diminishing their attractiveness and, in some cases, rendering them unsuitable from a commercial standpoint. For example, several ACE inhibitor-containing compositions suffer from this drawback since certain ACE inhibitors degrade readily in pharmaceutical dosage forms. For example, quinapril, enalapril, and spirapril degrade readily in dosage form to a diketo piperazine (the internal cyclization product) and a diacid (the ester hydrolysis product). It is believed that one or more of these types of degradation including oxidation causes the discoloration in pharmaceutical compositions containing ACE inhibitors. In addition, the degradation products may result in decreased drug effectiveness in such pharmaceutical compositions. Accordingly, in view of their usefulness in treating hypertension, a number of research endeavors have been directed to overcoming the instability problem associated with pharmaceutical compositions containing ACE inhibitors, with limited success.

Various methods of improving the stability of certain ACE inhibitors have been disclosed. U.S. Patent No. 4,743,450 discloses that certain ACE inhibitors, and in particular, quinapril and its acid addition salts can be stabilized by making solid compositions that include an alkali or alkaline earth metal carbonate, preferably magnesium carbonate, and a saccharide, specifically a sugar, such as mannitol or lactose. U.S. Patent No. 4,793,998 discloses that certain ACE inhibitors, and in particular, quinapril and its acid addition salts can be stabilized by making solid compositions that include ascorbic acid, and optionally one or more acids selected from citric, fumaric and maleic acids. U.S. Patent No. 4,830,853 discloses that

certain ACE inhibitors, and in particular, quinapril and its acid addition salts can be stabilized by making solid compositions that include ascorbic acid or a metal or ammonium ascorbate.

Although each of the above patents represents an attempt to overcome the instability problems associated with pharmaceutical compositions containing an ACE inhibitor, there still exists a need for improving the stability of such pharmaceutical compositions, especially in the presence of moisture.

Summary of the Invention

The invention provides a pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutically acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the weight percents are based on the total weight of the pharmaceutical composition.

According to another aspect, the invention provides a method of preparing a pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutically acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the weight percents are based on the total weight of the pharmaceutical composition, said method comprising:

- (a) mixing the ACE inhibitor or a pharmaceutically acceptable salt thereof, an alkali or alkaline earth metal carbonate, hydroxypropyl cellulose, and optionally one or more excipients, to form a premix;
- (b) adding a solvent, and optionally one or more excipients, to the premix formed in Step (a) to form a wet granulation;
- (c) drying the wet granulation to form granules, and optionally milling the granules; and
- (d) optionally mixing one or more excipients with the granules to form a pharmaceutical composition.

Preferably, the pharmaceutical composition of the invention is stable, and the formation of an internal cyclization product, and/or ester hydrolysis product, and/or oxidation product within the composition, has been reduced or eliminated.

In a further aspect, the pharmaceutical composition of the invention comprises an ACE inhibitor which is selected from the group consisting of quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazapril, libenzapril, delapril, cilazapril, and combinations thereof.

The stabilized pharmaceutical compositions of the invention exhibit a number of advantages as follows: (i) the ACE inhibitor or a pharmaceutical acceptable salt thereof present in the compositions is preserved from degradation; (ii) the compositions exhibit extended shelf-life under normal storage conditions; (iii) the effect of moisture on the compositions is minimized; (iv) the compositions exhibit minimal, if any, discoloration over a significant period of time; and (v) the compositions exhibit minimal, if any, instability when employed in the presence of colorants.

Description of the Invention

The pharmaceutical composition of the invention contains an ACE inhibitor or a pharmaceutically acceptable salt thereof, an alkali or alkaline earth metal carbonate, and hydroxypropyl cellulose. The ACE inhibitor is selected from quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazapril, libenzapril, delapril, and cilazapril. A combination of ACE inhibitors may also be used. Preferably, the ACE inhibitor is selected from quinapril, enalapril, and spirapril. More preferably, the ACE inhibitor is quinapril hydrochloride. It is noted that the ACE inhibitor may form a salt with various inorganic and organic acids and bases, which salts may be prepared by conventional methods.

The amount of ACE inhibitor or a pharmaceutically acceptable salt thereof in the pharmaceutical compositions is preferably from about 1 wt. % to about 80 wt. %, based on the total weight of the pharmaceutical composition. More preferably, the amount of ACE inhibitor or a pharmaceutically acceptable salt thereof is from about 5 wt. % to about

50 wt. %, most preferably about 10 wt. % to about 15 wt. %. As indicated above, ACE inhibitors including pharmaceutically acceptable salts thereof are known and their usefulness in treating hypertension is also well known. Accordingly, the daily dosages at which said ACE inhibitors or pharmaceutically acceptable salts thereof are employed as well as typical unit dosages of said ACE inhibitors or pharmaceutically acceptable salts thereof are well documented in the literature. Preferably, the ACE inhibitor or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in an amount of from about 1 mg to about 100 mg.

The alkali or alkaline earth metal carbonate is a salt which is prepared by reacting an alkali metal or alkaline earth metal with carbonic acid. The alkali metal is selected from lithium, sodium, potassium, rubidium, caesium and francium. The alkaline earth metal is selected from magnesium, calcium, barium, strontium and radium. Magnesium, calcium and sodium are the preferred metals. Most preferably, the metal is magnesium.

The amount of the alkali or alkaline earth metal carbonate in the pharmaceutical compositions is from about 1 wt. % to about 70 wt. %, based on the total weight of the pharmaceutical composition. Preferably, the amount of the alkali or alkaline earth metal carbonate is from about 10 wt. % to about 60 wt. %, more preferably about 45 wt. % to about 55 wt. %.

Hydroxypropyl cellulose is a partially substituted poly(hydroxypropyl) ether of cellulose. Hydroxypropyl cellulose is commercially available in a number of different grades which have different solution viscosities. The molecular weight of the hydroxypropyl cellulose ranges from about 50,000 to about 1,250,000. A preferred hydroxypropyl cellulose is available from Aqualon under the trademark KLUCEL. Suitable grades of hydroxypropyl cellulose include the following:

- 1) KLUCEL EF having a molecular weight of about 80,000;
- 2) KLUCEL LF having a molecular weight of about 95,000;
- 3) KLUCEL JF having a molecular weight of about 140,000;
- 4) KLUCEL GF having a molecular weight of about 370,000;
- 5) KLUCEL MF having a molecular weight of about 850,000; and
- 6) KLUCEL HF having a molecular weight of about 1,150,000.

Preferably, the hydroxypropyl cellulose is a low-substituted hydroxypropyl cellulose. The low-substituted hydroxypropyl cellulose (L-HPC) useful in the pharmaceutical compositions of the invention is available in a number of different grades which have different particle sizes and substitution levels, and which are classified on the basis of their % hydroxypropoxy content. When dried at 105 °C for 1 hour, the L-HPC contains from about 5% to about 16% of hydroxypropoxy groups, preferably from about 10% to about 13% of hydroxypropoxy groups. Suitable grades of L-HPC include the following:

- 1) LH-11 having a hydroxypropoxy content of 11% and an average particle size of 50 microns;
- 2) LH-21 having a hydroxypropoxy content of 11% and an average particle size of 40 microns;
- 3) LH-31 having a hydroxypropoxy content of 11% and an average particle size of 25 microns;
- 4) LH-22 having a hydroxypropoxy content of 8% and an average particle size of 40 microns;
- 5) LH-32 having a hydroxypropoxy content of 8% and an average particle size of 25 microns;
- 6) LH-20 having a hydroxypropoxy content of 13%, and an average particle size of 40 microns; and
- 7) LH-30 having a hydroxypropoxy content of 13%, and an average particle size of 25 microns.

Preferred L-HPCs are commercially available from Shin-Etsu Chemical Company under the trade designation L-HPC Grade LH-21 and LH-11.

The amount of hydroxypropyl cellulose in the pharmaceutical compositions is from about 1 wt. % to about 80 wt. %, based on the total weight of the pharmaceutical composition. Preferably, the amount of hydroxypropyl cellulose is from about 10 wt. % to about 50 wt. %, more preferably about 30 wt. % to about 40 wt. %.

The pharmaceutical compositions of the invention may also contain one or more excipients that are normally employed in pharmaceutical formulations, the only qualification being that they must not deleteriously affect the stability of the pharmaceutical compositions. Examples of such excipients are surfactants, diluents, binders, amino acids, solubilizers, disintegrants,

fillers, lubricants, buffers, stabilizers, colorants, dyes, anti-oxidants, anti-adherents, preservatives and glidants. A combination of excipients may also be used. Such excipients are known to those skilled in the art, and thus, only a limited number will be specifically referenced.

Examples of fillers include microcrystalline cellulose, dibasic calcium phosphate dihydrate, calcium sulfate trihydrate and calcium sulfate dehydrate. A combination of fillers may also be used. Preferably, the pharmaceutical composition of the invention does not contain a saccharide, specifically a sugar, such as lactose or mannitol. In addition, preferably the pharmaceutical composition of the invention does not contain starch.

Examples of lubricants include magnesium stearate, sodium stearate, calcium stearate, zinc stearate, talc, propylene glycol, PEG, stearic acid, vegetable oil, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, mineral oil and polyoxyethylene monostearate. A combination of lubricants may also be used. A preferred lubricant is magnesium stearate.

Examples of binders include gums, such as gum tragacanth, acacia gum and gelatin; microcrystalline cellulose, e.g., products known under the registered trademarks Avicel, Filtrak, Heweten or Pharmaceel, hydroxyethyl cellulose and hydroxypropylmethyl cellulose; and polyvinyl pyrrolidone, e.g., Povidone.

Examples of glidants include silica, magnesium trisilicate, powdered cellulose, talc, calcium silicate, and tribasic calcium phosphate. Colloidal silica, e.g., Aerosil, is particularly preferred.

Examples of disintegrants include:

- (i) cross-linked polyvinylpyrrolidones, e.g., crospovidones, such as Polyplasdone[®] XL and Kollidon[®] CL;
- (ii) alginic acid and sodium alginate;
- (iii) methacrylic acid-divinylbenzene co-polymer salts, e.g., Amberlite[®] IRP-88; and
- (iv) cross-linked sodium carboxymethylcellulose, available as, e.g., Ac-di-sol[®], Primellose[®], Pharmaceel[®] XL, Explocel[®] and Nymcel[®] ZSX.

Additional disintegrants also include hydroxypropylmethyl cellulose, croscarmellose sodium, polacrilin potassium, polyacrylates, such as Carbopol®, magnesium aluminium silicate and bentonite.

The pharmaceutical compositions of the invention can be prepared by any of the conventionally employed processing techniques such as dry granulation or wet granulation process. Wet granulation is preferably chosen to ensure a homogeneous distribution of the ACE, alkali or alkaline earth metal carbonate, and low-substituted hydroxypropyl cellulose.

In one embodiment of the invention, the pharmaceutical composition is prepared by a process comprising:

- (a) mixing the ACE inhibitor or a pharmaceutically acceptable salt thereof, an alkali or alkaline earth metal carbonate, hydroxypropyl cellulose, and optionally one or more excipients, to form a premix;
- (b) adding a solvent, and optionally one or more excipients, to the premix formed in Step (a) to form a wet granulation;
- (c) drying the wet granulation to form granules, and optionally milling the granules; and
- (d) optionally mixing one or more excipients with the granules to form a pharmaceutical composition.

Examples of solvents to be used in the wet granulation process include water, methanol, ethanol, isopropanol, acetone and ethylene chloride. A combination of solvents may also be used. Preferably, the solvent is water.

Drying techniques useful for drying the granulation include spray-drying, fluid bed, flash drying, ring drying, micron drying, tray drying, vacuum drying, radio-frequency drying and microwave drying.

The pharmaceutical compositions of the invention may be in the form of a capsule, caplet, bar, block, powder, disc or tablet, or in the form of granules. In a preferred embodiment, the pharmaceutical compositions are in the form of a tablet.

The following non-limiting examples illustrate further aspects of the invention.

The L-HPC used in the examples is commercially available from Shin-Etsu Chemical Company under the trade designation L-HPC Grade LH-21.

Example 1

Preparation of Quinapril Hydrochloride 40 mg Tablets.

Item #	Ingredients	mg/tablet
1	Quinapril Hydrochloride	43.33
2	Magnesium Carbonate	200.0
3	Microcrystalline Cellulose pH 102	0.0
4	L-HPC	136.67
5	Crospovidone	16.0
6	Magnesium Stearate	4.0
7	Methocel E15 LV	8.0
8	Triethyl Citrate	0.8
9	Opadry Beige YS-1-2718	8.0
10	Purified Water	q.s.
Total		416.8

The tablet composition is prepared by:

- (a) mixing quinapril hydrochloride, magnesium carbonate, and L-HPC to form a premix;
- (b) adding water to the premix formed in Step (a) to form a wet granulation under high shear granulation conditions;
- (c) drying the wet granulation in a fluid bed, and co-milling the dried granules;
- (d) V-blending the crospovidone and magnesium stearate with the granules to form a composition which is compressed on a Manesty Beta Press to form tablets; and
- (e) coating the tablets formed in Step (d) with Methocel and triethyl citrate using a Accela Cota; and
- (f) color coating the tablets formed in Step (e) with Opadry Beige using an Accela Cota.

Example 2

Preparation of Quinapril Hydrochloride 40 mg Tablets.

Item #	Ingredients	mg/tablet
1	Quinapril Hydrochloride	43.33
2	Magnesium Carbonate	200.0
3	Microcrystalline Cellulose pH 102	136.67
4	L-HPC	0.0
5	Crospovidone	16.0
6	Magnesium Stearate	4.0
7	Methocel E15 LV	8.0
8	Triethyl Citrate	0.8
9	Opadry Beige YS-1-2718	8.0
10	Purified Water	q.s.
Total		416.8

The quinapril tablets are prepared according to the procedure set forth in Example 1.

Example 3

Preparation of Quinapril Hydrochloride 40 mg Tablets.

Item #	Ingredients	mg/tablet
1	Quinapril Hydrochloride	43.33
2	Magnesium Carbonate	200.0
3	Microcrystalline Cellulose pH 102	68.34
4	L-HPC	68.33
5	Crospovidone	16.0
6	Magnesium Stearate	4.0
7	Methocel E15 LV	8.0
8	Triethyl Citrate	0.8
9	Opadry Beige YS-1-2718	8.0
10	Purified Water	q.s.
Total		416.8

The quinapril tablets are prepared according to the procedure set forth in Example 1.

Example 4

Preparation of Quinapril Hydrochloride 40 mg Tablets.

Item #	Ingredients	mg/tablet
1	Quinapril Hydrochloride	43.33
2	Magnesium Carbonate	200.0
3	Microcrystalline Cellulose pH 102	100.0
4	L-HPC	36.67
5	Crospovidone	16.0
6	Magnesium Stearate	4.0
7	Methocel E15 LV	8.0
8	Triethyl Citrate	0.8
9	Opadry Beige YS-1-2718	8.0
10	Purified Water	q.s.
Total		416.8

The quinapril tablets are prepared according to the procedure set forth in Example 1.

Example 5

The stability of the tablets prepared in Examples 1-4 is determined by the amount of degradation products according at 40 °C and 75% relative humidity.

Table 1.

Tablet	Quinapril (%)	Degradation Product Quinaprilate (wt. %)	Degradation Product DKP (wt. %)
Example 1	99.9	0.733	0.173
Example 2	91.5	2.281	0.132
Example 3	92.7	1.421	0.138
Example 4	96.8	0.924	0.140

The test results in Table 1 clearly show that Example 2 which is prepared with magnesium carbonate but without hydroxypropyl cellulose has a significantly high level of degradation product quinaprilate.

Degradation product DKP is understood to mean the diketo piperazine degradation product as herein mentioned.

While the invention has been described with particular reference to certain embodiments thereof, it will be understood that changes and modifications may be made by those of ordinary skill within the scope and spirit of the following claims:

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutically acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the weight percents are based on the total weight of the pharmaceutical composition.
2. A pharmaceutical composition according to claim 1 which is stable, and wherein the formation of an internal cyclization product, and/or ester hydrolysis product, and/or oxidation product, has been reduced or eliminated.
3. The composition according to claim 1 or 2 wherein the ACE inhibitor is selected from the group consisting of quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazapril, libenzapril, delapril, cilazapril and combinations thereof.
4. The composition according to any of claims 1 to 3, wherein the ACE inhibitor is selected from the group consisting of quinapril, enalapril and spirapril.
5. The composition according to any preceding claim, wherein the ACE inhibitor is quinapril hydrochloride.
6. The composition according to any preceding claim, wherein the amount of the ACE inhibitor or a pharmaceutically acceptable salt thereof is from about 5 wt. % to about 50 wt. %, based on the total weight of the pharmaceutical composition.
7. The composition according to claim 6, wherein the amount of the ACE inhibitor or a pharmaceutically acceptable salt thereof is from about 10 wt. % to about 15 wt. %, based on the total weight of the pharmaceutical composition.
8. The composition according to any preceding claim, wherein the alkali metal is selected from the group consisting of lithium, sodium, potassium, rubidium, caesium and francium.

9. The composition according to any preceding claim, wherein the alkaline earth metal is selected from the group consisting of magnesium, calcium, barium, strontium and radium.
10. The composition according to claim 9, wherein the alkaline earth metal is magnesium.
11. The composition according to any preceding claim, wherein the amount of the alkali or alkaline earth metal carbonate is from about 10 wt. % to about 60 wt. %, based on the total weight of the pharmaceutical composition.
12. The composition according to claim 11, wherein the amount of the alkali or alkaline earth metal carbonate is from about 45 wt. % to about 55 wt. %, based on the total weight of the pharmaceutical composition.
13. The composition according to any preceding claim, wherein the hydroxypropyl cellulose has a molecular weight of from about 50,000 to about 1,250,000.
14. The composition according to claim 13 wherein the hydroxypropyl cellulose has a molecular weight of from about 80,000 to about 1,150,000.
15. The composition according to any preceding claim, wherein the hydroxypropyl cellulose is a low-substituted hydroxypropyl cellulose (L-HPC).
16. The composition according to claim 15, wherein the low-substituted hydroxypropyl cellulose when dried at 105 °C for 1 hour contains 5-16% of hydroxypropoxy groups.
17. The composition according to claim 16, wherein the low-substituted hydroxypropyl cellulose when dried at 105 °C for 1 hour contains 10-13% of hydroxypropoxy groups.
18. The composition according to any of claims 15 to 17, wherein the low-substituted hydroxypropyl cellulose is selected from the group consisting of: LH-11 having a hydroxypropoxy content of 11% and an average particle size of 50 microns; LH-21 having a hydroxypropoxy content of 11% and an average particle size of 40 microns; LH-31 having a hydroxypropoxy content of 11%, and an average particle size of

25 microns; LH-22 having a hydroxypropoxy content of 8%, and an average particle size of 40 microns; LH-32 having a hydroxypropoxy content of 8%, and an average particle size of 25 microns; LH-20 having a hydroxypropoxy content of 13%, and an average particle size of 40 microns; and LH-30 having a hydroxypropoxy content of 13%, and an average particle size of 25 microns.

19. The composition according to claim 18, wherein the L-HPC is LH-21 or LH-11.
20. The composition according to any preceding claim, wherein the hydroxypropyl cellulose is present in an amount of from about 10 wt. % to about 50 wt. %.
21. The composition according to claim 20, wherein the hydroxypropyl cellulose is present in an amount of from about 30 wt. % to about 40 wt. %.
22. The composition according to any preceding claim, which is in the form selected from the group consisting of a tablet, bar, block, disc, capsule, caplet, powder and granules.
23. A method of preparing a pharmaceutical composition according to any of claims 1 to 3, said method comprising:
 - (a) mixing the ACE inhibitor or a pharmaceutically acceptable salt thereof, an alkali or alkaline earth metal carbonate, hydroxypropyl cellulose, and optionally one or more excipients, to form a premix;
 - (b) adding a solvent, and optionally one or more excipients, to the premix formed in Step (a) to form a wet granulation;
 - (c) drying the wet granulation to form granules, and optionally milling the granules;and
 - (d) optionally mixing one or more excipients with the granules to form a pharmaceutical composition.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/007591

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/00 A61K31/00 A61K47/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 280 999 A (WARNER LAMBERT CO) 7 September 1988 (1988-09-07) claims 1-10; examples A-D	1-23
A	US 4 584 299 A (EVANS DALE B ET AL) 22 April 1986 (1986-04-22) claims 1-7	1-23
A	US 5 151 433 A (STAMMBERGER WILLI ET AL) 29 September 1992 (1992-09-29) column 6 - column 7, line 50	1-23
A	EP 0 288 732 A (SQUIBB & SONS INC) 2 November 1988 (1988-11-02) page 9; claims 1-21	1-23
	----- -/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

23 November 2004

Date of mailing of the international search report

03/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kardas-Llorens, E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/007591

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category ^	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 298 497 A (TSCHOLLAR WERNER ET AL) 29 March 1994 (1994-03-29) column 16, line 17 - line 23; claim 1; examples 7,13 -----	1-23
A	WO 94/01093 A (MERCK & CO INC ; RORK GERALD S (US); HASLAM JOHN L (US)) 20 January 1994 (1994-01-20) page 5 - page 10; claims 1,15,19 -----	1-23
A	GU L ET AL: "DRUG-EXCIPIENT INCOMPATIBILITY STUDIES OF THE DIPEPTIDE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, MOEXIPRIL HYDROCHLORIDE: DRY POWDER VS WET GRANULATION" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 7, no. 4, 1990, pages 379-383, XP009009003 ISSN: 0724-8741 page 381 - page 383 -----	1-23
A	AL-OMARI M M ET AL: "Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations" JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 25, no. 5-6, July 2001 (2001-07), pages 893-902, XP002241568 ISSN: 0731-7085 page 898 - page 900 -----	1-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/007591

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0280999	A	07-09-1988	US	4743450 A	10-05-1988
			AT	84210 T	15-01-1993
			AU	597471 B2	31-05-1990
			AU	1130588 A	25-08-1988
			CA	1300510 C	12-05-1992
			DE	3877226 D1	18-02-1993
			DE	3877226 T2	29-04-1993
			DK	94088 A	25-08-1988
			EP	0280999 A2	07-09-1988
			HK	59496 A	12-04-1996
			IE	60931 B1	07-09-1994
			JP	2619904 B2	11-06-1997
			JP	63225322 A	20-09-1988
			NZ	223407 A	29-08-1989
			PH	26279 A	10-04-1992
			ZA	8800382 A	27-09-1989
US 4584299	A	22-04-1986	NONE		
US 5151433	A	29-09-1992	DE	3739690 A1	08-06-1989
			AT	74513 T	15-04-1992
			AU	2581888 A	25-05-1989
			CA	1338344 C	21-05-1996
			CN	1042917 A , B	13-06-1990
			DE	3869919 D1	14-05-1992
			DK	653688 A	25-05-1989
			EP	0317878 A1	31-05-1989
			ES	2033400 T3	16-03-1993
			FI	885398 A , B,	25-05-1989
			GR	3004925 T3	28-04-1993
			HU	48455 A2	28-06-1989
			IE	61173 B1	05-10-1994
			JP	1165596 A	29-06-1989
			JP	2049604 C	10-05-1996
			JP	7068140 B	26-07-1995
			KR	9704908 B1	08-04-1997
			NO	885213 A , B,	25-05-1989
			NZ	227032 A	28-05-1991
			PH	27416 A	21-06-1993
			PT	89061 A , B	01-12-1988
			US	5442008 A	15-08-1995
			ZA	8808734 A	26-07-1989
EP 0288732	A	02-11-1988	AU	613898 B2	15-08-1991
			AU	1283588 A	03-11-1988
			CA	1323833 C	02-11-1993
			CN	1041103 A , B	11-04-1990
			DD	272998 A5	01-11-1989
			DK	230288 A	29-10-1988
			EP	0288732 A2	02-11-1988
			HU	52944 A2	28-09-1990
			JP	63284123 A	21-11-1988
			KR	9606060 B1	08-05-1996
			NZ	223713 A	26-06-1990
			PH	26689 A	15-09-1992
			US	4808413 A	28-02-1989
			ZA	8801488 A	22-08-1988

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/007591

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 5298497	A	29-03-1994	US US	5461039 A 5593971 A		24-10-1995 14-01-1997
WO 9401093	A	20-01-1994	AU WO	4660993 A 9401093 A1		31-01-1994 20-01-1994